WHO vaccine-preventable diseases: monitoring system. 2018 global summary

Last updated 1-Jun.-2018 (data as of 25-May-2018)
Next overall update Mid-July 2018
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 8'4301 Infant (under 12 months) mortality rate: 142
GDP / capita (US$): 12'9671 Child (under 5 years) mortality rate: 162

Population data in thousands3

  2017  2016  2015  2014  2013  2000  1990  1980 
Total population 108  107  107  106  106  102  96  89 
Births
Surviving infants
Pop. less than 5 years 10  10  10  10  10  10  15  12 
Pop. less than 15 years 28  28  28  28  28  36  37  36 
Female 15-49 years 28  28  28  28  28  25  21  20 

Number of reported cases

(Click for retrospective incidence data for Grenada)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  53 
Mumps
ChartChart
 
Pertussis
ChartChart
 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Grenada)
Vaccine year result method % card seen                                                
BCG         
DTP1          77  91  94  97  99  99* 
DTP3          83  96  92  97  99*  97  80  25 
DTP4          83  87  91  93 
IPV1          91  90  54 
HepB_BD          78  35 
HepB3          83  96  92  97  99* 
Hib3          83  96  92  97  99*  33 
JapEnc         
MCV1          85  95  99  94  99*  92  85 
MCV2          79  85  89  92  85 
MenA         
PCV1         
PCV2         
PCV3         
Pol3          91  98  99  81  99*  97  69  32 
Rota1         
RotaC         
RCV1          85  95  99  94  98 
TT2plus          14  12  11  11 
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Grenada)
DTP1
ChartChart
  94  94  97  99  99  93  50 
DTP3
ChartChart
  92  92  97  97  97  80  25 
HepB3
ChartChart
  92  92  97  97 
HepB_BD
ChartChart
 
Hib3
ChartChart
  92  92  97  97  33 
IPV1
  54  54 
MCV1
ChartChart
  99  99  94  94  92  85 
MCV2
ChartChart
  89  89  92  85 
PCV3
 
Pol3
ChartChart
  99  99  81  98  97  69  32 
RCV1
ChartChart
  99  99  94  94  92 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 0
From 80 to 89% 43
From 50 to 79% 57
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2017 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DT 4-5 years; Yes
DTwP 18 months; Yes
DTwPHibHepB 6-8, 16-20, 24-28 weeks; Yes
HepB_Adult 1st contact; +1, +5 months; Yes risk groups
HepB_Pediatric birth; Yes
HPV 9-10 years (x2); Yes from November 2018; females (grades 4 and 5)
Influenza_Adult Yes residents of elderly homes, adults with chronic illness, pregnant women, health care workers, other risk groups
Influenza_Pediatric 6 months-18 years; Yes and children with chronic illness
IPV 6-8 weeks; Yes
MMR 12, 18 months; Yes
OPV 16-20, 24-28 weeks; 18 months; 4-5, >=14 years; Yes
Pneumo_conj Yes from 2019; risk groups
Td 1st contact; +1, +6 months; +10 years; Yes for older children and adults; boosters every 10 years for risk groups
Varicella 12 months; Yes risk groups
YF 12 months; Yes risk groups

Immunizaton indicators

Indicator Expected answer 2017  2016  2015  2014  2013  2012  2011 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  NA  Yes  Yes  Yes 
What years does the MYP cover? number 2016- 2025  2016-2025  2016 -2025  NA  2013-2014  2011- 2012  2008 -2012 
Nº of districts with microplans that include activities to raise immunization coverage number

System performance

Total Nº districts in country number
Nº districts with DTP3 coverage >=80% number
% of districts with DTP3 coverage >=80% From 0 to 100% 43  86  71  86  86  100  86 
Nº districts with measles (MCV1) coverage >=95% number
% of districts with MCV1 coverage >=95% From 0 to 100% 43  43  57  29  57  43  71 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  No  No  No  No 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  No  No  No  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 98  97  68  92  92  95  98 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  No  No  No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2018
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.